OTC Markets OTCPK - Delayed Quote USD

GlobeStar Therapeutics Corporation (GSTC)

Compare
0.0004 +0.0001 (+33.33%)
At close: November 1 at 3:22 PM EDT
Currency in USD All numbers in thousands
Breakdown
TTM
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Total Revenue
--
--
--
--
0.0770
Cost of Revenue
--
--
--
2.4120
37.6820
Gross Profit
--
--
--
-2.4120
-37.6050
Operating Expense
804.5980
1,864.3700
1,265.0650
9,091.8170
266.0660
Operating Income
-804.5980
-1,864.3700
-1,265.0650
-9,094.2290
-303.6710
Net Non Operating Interest Income Expense
-82.3580
-91.6030
-70.3460
-287.4990
-238.0600
Other Income Expense
--
6.7240
-152.3990
-419.9000
--
Pretax Income
-886.9560
-1,949.2490
-1,487.8100
-9,801.6280
-541.7310
Net Income Common Stockholders
-919.2970
-1,949.2490
-1,487.8100
-9,801.6280
-541.7310
Diluted NI Available to Com Stockholders
-919.2970
-1,949.2490
-1,487.8100
-9,801.6280
-541.7310
Basic EPS
-0.00
-0.00
-0.00
-0.02
-0.00
Diluted EPS
-0.00
-0.00
-0.00
-0.02
-0.00
Basic Average Shares
1,069,128.8710
827,324.7890
628,539.7820
482,090.0990
298,091.1530
Diluted Average Shares
1,069,128.8710
827,324.7890
628,539.7820
482,090.0990
298,091.1530
Total Operating Income as Reported
-804.5980
-1,864.3700
-1,265.0650
-9,094.2290
-303.6710
Total Expenses
804.5980
1,864.3700
1,265.0650
9,094.2290
303.7480
Net Income from Continuing & Discontinued Operation
-886.9560
-1,949.2490
-1,487.8100
-9,801.6280
-541.7310
Normalized Income
-886.9560
-1,949.2490
-1,487.8100
-9,801.6280
-541.7310
Interest Expense
82.3580
91.6030
70.3460
287.4990
238.0600
Net Interest Income
-82.3580
-91.6030
-70.3460
-287.4990
-238.0600
EBIT
-804.5980
-1,857.6460
-1,417.4640
-9,514.1290
-303.6710
EBITDA
-804.5980
-1,857.6460
-1,417.4640
-9,512.8540
-302.3420
Reconciled Cost of Revenue
--
--
--
2.4120
37.6820
Reconciled Depreciation
--
--
--
1.2750
1.3290
Net Income from Continuing Operation Net Minority Interest
-886.9560
-1,949.2490
-1,487.8100
-9,801.6280
-541.7310
Total Unusual Items Excluding Goodwill
132.7080
--
--
--
--
Total Unusual Items
132.7080
--
--
--
--
Normalized EBITDA
-804.5980
-1,857.6460
-1,417.4640
-9,512.8540
-302.3420
9/30/2020 - 9/26/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers